Cardiology

AHA Scientific Sessions 2021 recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.

Get a quick look at 12 of the many FDA-approved drugs in 2021 for conditions commonly seen in primary care.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

Daily e-cigarette use was associated with more than twice the odds of reporting erectile dysfunction vs never using e-cigarettes, independent of other common ED risk factors.

Women and older adults had the highest increases in blood pressure levels during the pandemic, according to new research.

Find out how effective each of 8 ACC/AHA-recommended non-drug interventions is at reducing BP (in mm Hg) in adults with hypertension and normal BP.

In patients with biopsy-proven NASH, the SPLENDOR study is the first to report a medical modality associated with decreased risk of major adverse events.

Treatment with aspirin of patients with cardiovascular risk factors was consistently associated with a greater than 25% risk of incident HF, another strike against the OTC antithrombotic.

AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.

Patients taking either of the 2 anticoagulants showed no large differences on 4 cognitive test scores at 2 years, according to authors of the GIRAF trial.

Smoking was associated with earlier onset of cardiovascular disease, by 5.1 years for men and 3.8 years for women, the new study found.

AHA 2021. Heart failure patients, across ejection fraction and diabetes status, reported improved QOL as early as 3 months in CHIEF-HF trial.

AHA 2021: Study suggests remote hypertension and hyperlipidemia management programs may expand telehealth delivery, increase access to care, and reduce health inequities.

AHA 2021: Marcus, lead author of CRAVE, says it found little effect of caffeine on atrial arrhythmias, a significant effect on PVCs, a negative effect on sleep, and a boosting effect on physical activity.

AHA 2021: Novel software algorithm used in Fitbit wearable devices accurately detected undiagnosed atrial fibrillation about 98% of the time, showed results of the Fitbit Heart Study.

AHA 2021. Coffee increased PVCs by 54% in regular coffee drinkers and decreased sleep by more than 30 minutes; it also significantly increased daily step count and slightly improved SVT.

AHA Scientific Sessions 2021: New research provides a note of caution for the use of digital heart failure coaching apps in severely ill and elderly patients with unstable heart failure.

AHA Scientific Sessions 2021: Employment status and higher caregiver burden were linked to increased engagement with a videoconferencing-based intervention to reduce the risk of CVD.

EHR-integrated remote BP monitoring was evaluated in a primary care Medicare population to assess uptake and initial effects on hypertension management.

Chest pain evaluation requires timely and accurate distinction between serious and benign causes. The 2021 ACC/AHA guideline authors provide 10 important reminders.

AHA Scientific Sessions 2021. Statin-associated muscle symptoms complicate treatment initiation and adherence; a new mHealth tool shows promise in reducing treatment cessation.

AHA Scientific Sessions 2021: Blood pressure reductions to clinical targets were achieved by patients with sustained hypertension through a remote health care delivery program during the COVID-19 pandemic.

AHA Scientific Sessions 2021: New research found living in socially vulnerable neighborhoods increased the risk of myocardial infarction, stroke, or death among hospitalized COVID-19 patients.

AHA Scientific Sessions 2021: National study of over 2.9 million young Black adults showed increased rates of CVD risk factors and worsened hospital outcomes between 2007 and 2017.

A clinical psychologist from the Mayo Clinic Bariatric Center in Jacksonville, FL, explains and corrects key misperceptions that inhibit open discussion of the therapy.